IPO - CNS Pharmaceuticals, Inc.

Form Type: S-1

Filing Date: 2025-04-14

Corporate Action: Ipo

Type: New

Accession Number: 000168316825002548

Filing Summary: CNS Pharmaceuticals, Inc. is filing a registration statement under the Securities Act of 1933 for the offering of up to 5,223,880 shares of common stock and associated warrants. The offering is intended to commence as soon as practicable after the effective date of the registration statement. Common stock and warrants will be issued separately but will be purchased together. The proposed pricing for the offering is based on an assumed combined public offering price of $1.34 per share. The securities are targeted for a continuous offering under Rule 415. CNS Pharmaceuticals, being classified as an emerging growth company, will comply with reduced public reporting requirements. The company's focus is on developing anti-cancer drug candidates, specifically TPI 287 and Berubicin, aimed at treating CNS tumors. Berubicin has shown promise in clinical trials for Glioblastoma Multiforme. The stock is currently traded on the Nasdaq under the symbol CNSP. The last reported sale price was $1.34 per share as of April 11, 2025. The offering will end no later than April 30, 2025, and a single closing for the sale of securities is expected with investors funding the purchase. The placement agent engaged is A.G.P./Alliance Global Partners, and they will use reasonable efforts to arrange the sale of securities in this offering. The clinical and market environment, particularly regarding the promising outcomes of Berubicin, positions CNS Pharmaceuticals favorably for potential approval and market entry.

Document Link: View Document

Form Type: DRS

Filing Date: 2025-04-07

Corporate Action: Ipo

Type: New

Accession Number: 000168316825002312

Filing Summary: CNS Pharmaceuticals, Inc. filed a confidential draft registration statement on Form S-1 with the SEC on April 7, 2025, related to an initial public offering (IPO) of securities. The company is offering up to 6,363,637 shares of common stock at an assumed combined public offering price of $1.10 per share, accompanied by Series F warrants to purchase the same number of common shares. Additionally, the company is offering pre-funded warrants for the purchase of an equivalent number of shares to prevent certain investors from exceeding ownership limits over 4.99% or 9.99% of outstanding shares. This prospectus includes the terms and conditions of the offering, a summary of the company’s background, information about its drug candidates TPI 287 and Berubicin, and highlights their clinical significance, particularly in treating aggressive brain cancers like Glioblastoma. The document outlines their current status in clinical trials and discusses existing intellectual property arrangements, including collaborations aimed at enhancing their drug development efforts. The offering period is expected to conclude by April 30, 2025, with no minimum offering amount required to close the offering.

Document Link: View Document